<?xml version='1.0' encoding='utf-8'?>
<document id="29574693"><sentence text="Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure." /><sentence text="Prospectively defining the physiological and molecular characteristics most likely driving between-subject variability (BSV) in drug exposure provides the opportunity to inform the assessment of biomarkers to account for this variability" /><sentence text=" A physiologically based pharmacokinetic (PBPK) model was constructed and verified for dabrafenib"><entity charOffset="87-97" id="DDI-PubMed.29574693.s3.e0" text="dabrafenib" /></sentence><sentence text=" This model was then used to evaluate the physiological and molecular characteristics driving BSV in dabrafenib exposure"><entity charOffset="101-111" id="DDI-PubMed.29574693.s4.e0" text="dabrafenib" /></sentence><sentence text=" The capacity to discriminate a steady-state dabrafenib trough concentration &gt;48 ng/mL was also evaluated"><entity charOffset="45-55" id="DDI-PubMed.29574693.s5.e0" text="dabrafenib" /></sentence><sentence text=" The mean simulated/observed ratios for the parameters describing dabrafenib exposure in single-dose, multiple-dose, and drug-drug interaction studies were between 0"><entity charOffset="66-76" id="DDI-PubMed.29574693.s6.e0" text="dabrafenib" /></sentence><sentence text="78 and 1" /><sentence text="23" /><sentence text=" Multivariable analysis indicated that consideration of baseline weight, body mass index, and CYP2C8, CYP3A4, and P-gp abundance strongly predicts steady-state dabrafenib trough concentration above 48 ng/mL (ROC AUC = 0" /><sentence text="94; accuracy = 86%)" /><sentence text=" This is the first study to use a verified PBPK model to identify baseline physiological and molecular characteristics driving BSV in drug exposure" /><sentence text="" /></document>